Logo image of CFRX

CONTRAFECT CORP (CFRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CFRX - US2123264093 - Common Stock

0.2318 USD
+0.01 (+2.84%)
Last: 11/8/2023, 8:26:06 PM
0.171 USD
-0.06 (-26.23%)
After Hours: 11/8/2023, 8:26:06 PM
Fundamental Rating

1

Overall CFRX gets a fundamental rating of 1 out of 10. We evaluated CFRX against 531 industry peers in the Biotechnology industry. CFRX has a bad profitability rating. Also its financial health evaluation is rather negative. CFRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CFRX had negative earnings in the past year.
In the past year CFRX has reported a negative cash flow from operations.
CFRX had negative earnings in each of the past 5 years.
In the past 5 years CFRX always reported negative operating cash flow.
CFRX Yearly Net Income VS EBIT VS OCF VS FCFCFRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -186.23%, CFRX is not doing good in the industry: 91.87% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -186.23%
ROE N/A
ROIC N/A
ROA(3y)-133.5%
ROA(5y)-110.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CFRX Yearly ROA, ROE, ROICCFRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 5K 10K 15K 20K 25K

1.3 Margins

CFRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CFRX Yearly Profit, Operating, Gross MarginsCFRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022

More info and screens

1

2. Health

2.1 Basic Checks

The number of shares outstanding for CFRX has been increased compared to 1 year ago.
CFRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CFRX Yearly Shares OutstandingCFRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 100K 200K 300K 400K 500K
CFRX Yearly Total Debt VS Total AssetsCFRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -31.04, we must say that CFRX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -31.04, CFRX is not doing good in the industry: 94.03% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -31.04
ROIC/WACCN/A
WACCN/A
CFRX Yearly LT Debt VS Equity VS FCFCFRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 1.00 indicates that CFRX should not have too much problems paying its short term obligations.
The Current ratio of CFRX (1.00) is worse than 90.38% of its industry peers.
CFRX has a Quick Ratio of 1.00. This is a normal value and indicates that CFRX is financially healthy and should not expect problems in meeting its short term obligations.
CFRX has a worse Quick ratio (1.00) than 89.22% of its industry peers.
Industry RankSector Rank
Current Ratio 1
Quick Ratio 1
CFRX Yearly Current Assets VS Current LiabilitesCFRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 61.60% over the past year.
EPS 1Y (TTM)61.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CFRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.78% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y96.87%
EPS Next 2Y40.94%
EPS Next 3Y25.78%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CFRX Yearly EPS VS EstimatesCFRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800 -1K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CFRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CFRX Price Earnings VS Forward Price EarningsCFRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CFRX Per share dataCFRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as CFRX's earnings are expected to grow with 25.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.94%
EPS Next 3Y25.78%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CFRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CONTRAFECT CORP

NASDAQ:CFRX (11/8/2023, 8:26:06 PM)

After market: 0.171 -0.06 (-26.23%)

0.2318

+0.01 (+2.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2023-11-13/bmo
Earnings (Next)03-29 2024-03-29/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners192.77%
Ins Owner Change0%
Market Cap1.27M
Revenue(TTM)N/A
Net Income(TTM)-35.85M
Analysts82.86
Price Target5.1 (2100.17%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.34%
Min EPS beat(2)-5.08%
Max EPS beat(2)93.75%
EPS beat(4)3
Avg EPS beat(4)33.11%
Min EPS beat(4)-5.08%
Max EPS beat(4)93.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)65.63%
EPS NY rev (1m)0%
EPS NY rev (3m)49.04%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-37.17
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-6.69
FCFYN/A
OCF(TTM)-6.67
OCFYN/A
SpS0
BVpS-0.2
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -186.23%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-133.5%
ROA(5y)-110.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1
Quick Ratio 1
Altman-Z -31.04
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)13.33%
Cap/Depr(5y)27.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)61.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%94.73%
EPS Next Y96.87%
EPS Next 2Y40.94%
EPS Next 3Y25.78%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y36.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y0.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.16%
OCF growth 3YN/A
OCF growth 5YN/A

CONTRAFECT CORP / CFRX FAQ

What is the fundamental rating for CFRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to CFRX.


What is the valuation status for CFRX stock?

ChartMill assigns a valuation rating of 1 / 10 to CONTRAFECT CORP (CFRX). This can be considered as Overvalued.


Can you provide the profitability details for CONTRAFECT CORP?

CONTRAFECT CORP (CFRX) has a profitability rating of 0 / 10.


What is the financial health of CONTRAFECT CORP (CFRX) stock?

The financial health rating of CONTRAFECT CORP (CFRX) is 1 / 10.